Form 4: CRISPR CEO Kulkarni Reports Routine Share Transactions

CRISPR Therapeutics CEO Samarth Kulkarni reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Summary

• Samarth Kulkarni, CEO and Director of CRISPR Therapeutics AG (CRSP), reported transactions involving the company's common shares.
• On October 13, 2025, 8,334 common shares were acquired through the vesting of restricted stock units (RSUs).
• This RSU vesting represents the second tranche of an award granted on October 13, 2023, for a total of 25,000 shares, vesting in three equal annual tranches.
• Following this acquisition, Kulkarni's direct beneficial ownership was 209,338 common shares.
• On October 14, 2025, Kulkarni disposed of 4,242 common shares at a price of $66.6 per share.
• This sale was non-discretionary and mandated by the company's RSU Settlement Policy to cover tax withholding obligations related to the RSU vesting.
• After the sale, Kulkarni's direct beneficial ownership decreased to 205,096 common shares.
• Kulkarni also indirectly beneficially owns 85,662 common shares through The Kulkarni 2023 GRAT.

Sentiment

Score: 5

Explanation: The filing reports routine, pre-scheduled insider transactions related to equity compensation and tax obligations, which are neither inherently positive nor negative for the company's operational or financial performance.

Positives

• The vesting of 8,334 restricted stock units indicates continued compensation and retention of the CEO, aligning management incentives with long-term company performance.
• The multi-year vesting schedule of the RSU award (granted October 13, 2023, vesting through October 13, 2026) promotes a long-term focus for executive leadership.

Negatives

• A sale of 4,242 common shares, even for tax purposes, reduces the CEO's direct equity stake in the company.

Future Outlook

The remaining one-third of the restricted stock unit award, representing 8,333 shares, is scheduled to vest on October 13, 2026.

Management Comments

• "Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person."

Industry Context

This filing is a routine disclosure of insider transactions, common across all publicly traded companies, particularly for executives receiving equity compensation like restricted stock units. It reflects standard compensation practices in the biotechnology and pharmaceutical sectors, where equity awards are a significant component of executive pay.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) with multi-year vesting schedules is a common practice in executive compensation across various industries, including biotechnology, aligning executive interests with long-term shareholder value.
• The mandatory sale of shares to cover tax obligations upon RSU vesting is a standard, non-discretionary mechanism to manage tax liabilities, widely observed in comparable companies like Vertex Pharmaceuticals (VRTX) or Moderna (MRNA) for their executive equity compensation plans.

Related Party Transactions

• Samarth Kulkarni indirectly beneficially owns 85,662 common shares through The Kulkarni 2023 GRAT.

Stakeholder Impact

• Shareholders: Minimal impact as the transactions are routine and non-discretionary, reflecting standard executive compensation practices. The CEO's overall equity exposure remains substantial.
• Employees: No direct impact.
• Customers: No direct impact.
• Suppliers: No direct impact.
• Creditors: No direct impact.

Next Steps

• The final one-third tranche of the restricted stock unit award (8,333 shares) is scheduled to vest on October 13, 2026.

Key Dates

Recommendation

This Form 4 details routine, non-discretionary transactions related to executive equity compensation and tax obligations. It provides no new material information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment thesis. The vesting of RSUs is a pre-scheduled event, and the associated tax sale is a standard practice, thus maintaining a 'hold' recommendation is appropriate based solely on this filing.

Keywords

CRISPR Therapeutics, CRSP, Samarth Kulkarni, CEO, Director, Form 4, Insider Transaction, Restricted Stock Units, RSU, Share Vesting, Tax Withholding, Equity Compensation